BioCentury
ARTICLE | Company News

Miltenyi acquires Living Pharma and its CAR T technology

July 28, 2017 8:23 PM UTC

The Lentigen Technology Inc. subsidiary of Miltenyi Biotec GmbH (Bergisch Gladbach, Germany) acquired immunotherapy company Living Pharma Inc. (Baltimore, Md.), gaining Living Pharma’s preclinical Anti-Tag CAR (AT-CAR) engineered T cell therapy technology. The companies will continue developing AT-CAR technology using Lentigen’s lentiviral vector technologies. A Miltenyi spokesperson said clinical trials of the product are expected in hematological cancers within one to two years. The companies declined to disclose financial terms...

BCIQ Company Profiles

Miltenyi Biotec B.V. & Co. KG